TRIM56 and ovarian carcinoma: In detail, PRDX6 competitively interacts with NNMT to prevent its binding to the E3 ubiquitin ligase TRIM56, resulting in the inhibition of ubiquitin‐mediated degradation of NNMT to activate MAPK signaling pathway and promote ovarian cancer progression (Figure 7G).